-
T-cell receptor (TCR) signalling(Page)
Services(Page)
Custom Research Services | Assay Genie
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
In Vivo depletion atlas(Page) Adalimumab: Mechanism, Clinical Applications, and the Role of Biosimilars(Post)Biologics · TNF InhibitionAdalimumab: Mechanism, Clinical Applications and BiosimilarsAdalimumab is a fully human IgG1 monoclonal antibody that binds tumour necrosis factor alpha and prevents it engag
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)Immunology · T LymphocytesCD8+ T Cells: Cytotoxic Mechanisms, Memory and ExhaustionCD8+ T cells kill infected and transformed cells directly, and they do it with a specificity nothing else in the immu
Bococizumab: Mechanism, Clinical Applications, and Biosimilars in Research(Post)Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi
Interactive Pathway Diagrams(Page) Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
Unlocking a New Immune Checkpoint: The CD47-Thrombospondin-1 Pathway in Cancer(Post)Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh
CD25 and Tregs: Understanding the Role of Regulatory T Cells in Tumor Immunity(Post)Regulatory T cells (Tregs) play a crucial role in maintaining immune balance by suppressing excessive immune responses that could lead to tissue damage. However, in the context of cancer,
Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
Breakthrough Discovery: Epstein-Barr Virus Identified as Primary Trigger for Lupus(Post)Breakthrough Discovery: Epstein-Barr Virus Identified as Primary Trigger for Lupus A groundbreaking study published in November 2025 has provided the most definitive evidence to date that the common E
FoxP3: Understanding Regulatory T Cell Control in Tumor Immunity(Post)Introduction to FoxP3 and Regulatory T Cells in CancerFoxP3 (forkhead box P3) is a transcription factor critical for the development and function of regulatory T cells (Tregs), a speciali
SITC 2024 - Scientific Programme, Venue & Exhibition(Post)SITC 2024: Meet Assay Genie at the Society for Immunotherapy of Cancer Annual MeetingAssay Genie is delighted to be attending and exhibiting at SITC 2024 in Houston, Texas on Friday the
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research(Post)Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
B7-H4: A New Frontier in Immune Checkpoint Inhibition(Post)The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
CD25+FOXP3+CD45RA- Treg Cells and Cancer Prognosis(Post)The Role of CD25+FOXP3+CD45RA- Treg Cells in Cancer PrognosisIntroductionRegulatory T-cells (Treg cells) are a specialized subset of T-cells that play a pivotal role in maintaining immune homeostasis
GITR: Boosting T Cell Activation for Enhanced Cancer Immunotherapy(Post)Glucocorticoid-induced tumor necrosis factor receptor (GITR) is an immune checkpoint molecule that plays a crucial role in regulating T cell activation and survival. In recent years, GITR
TIM-3/Gal-9 Pathway in Antiparasitic Immunity(Post)Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including
T Helper Cells: Th1, Th2, Th17 Differences & Functions [2026](Post)Complete T Helper Cell Guide: Th1, Th2, Th17 & Functions - Your Ultimate Resource from Assay GenieIn this guide, we will explore the differences between TH1 and TH2 cells, their crucial r
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting(Post)What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
BTLA: A Key Player in Immune Regulation and Cancer Therapy(Post)Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis(Post)Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
Multiplex Assays(Page)GeniePlex Multiplex Assays | Bead-Based Multiplex Immunoassays | Assay Genie
Immune-Checkpoint Inhibition in Cancer Prevention(Post)Harnessing Immune-Checkpoint Inhibition for Cancer Prevention Immune-checkpoint inhibition (ICI) has emerged as a pivotal strategy in cancer therapy, particularly in the context of tu
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
PVR: Balancing Immune Activation and Suppression in Cancer(Post)PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a r
Cytokine ELISA Kits(Page)High Sensitivity Cytokine ELISA Kits & Multiplex Panels | Assay Genie
Regulatory T-cell (Treg) suppression & the IL-2 axis(Page) KIR Blockade: Empowering NK Cells for Superior Tumor Clearance(Post)Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Custom ELISA Kits(Page)Custom ELISA Kit Development Service | Assay Genie
B-cell activation and the germinal centre reaction(Page) Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
LILT: A Novel Immune Checkpoint for Cancer Therapy(Post)Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr
T-Cell Co-Stimulation & Agonist Checkpoint Pathway(Page) Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research(Post)Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.
Cytokine neutralisation network(Page) Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress
High Sensitivity Cytokine ELISA Kits & Multiplex Panels(Page)High Sensitivity Cytokine ELISA Kits & Multiplex Panels | Assay Genie
NK cell activation & innate cytotoxicity(Page) Myeloid reprogramming in the tumour microenvironment(Page) Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
CAR-T cell signalling(Page) Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
ICOS: Stimulating the Immune System for Superior Cancer Therapy(Post)Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
Daratumumab: Advancing Research in Multiple Myeloma and Beyond(Post)Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
CD28: Amplifying T Cell Responses for Better Tumor Clearance(Post)The CD28 molecule plays a crucial role in amplifying T cell activation, which is critical for mounting effective immune responses against tumors. By engaging with co-stimulatory molecules
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
PharmaGenie ELISA Kits(Page)PharmaGenie ELISA Kits | ISO-Validated BioPharma ELISA | Assay Genie
PD-1 Blockade in B-Cell Lymphomas: A Comprehensive Overview(Post)Understanding PD-1 Blockade in B-Cell Lymphomas Understanding PD-1 Blockade in B-Cell Lymphomas Introduction The programmed cell death prote
TIGIT/DNAM-1/CD155 (PVR) Checkpoint Axis(Page) CD122: Fine-Tuning T Cell Responses in Immunotherapy(Post)Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and malign